Congress Materials - World Conference on Lung Cancer (WCLC 2026)
2026 World Conference on Lung Cancer | Sep 12-15 | Seoul, Republic of Korea
A Single-Arm Phase II Study of Amivantamab, Lazertinib, and Pemetrexed as First-Line Therapy for Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): AMIGO-1 (LACOG 0821)
William Nassib William Junior, Flavio Augusto Da Silva, Ana Caroline Gelatti, Manuela Zereu, Felipe José Silva Melo Cruz, Suellen Nastri Castro, Pedro de Marchi, Eduardo Henrique Cronemberger Costa e Silva, Sulene Cunha Sousa Oliveira, Gilberto de Castro Júnior, Herbert Palmeira, Bruno Cezar de Mendonça Uchôa Júnior, Tatiane Montella, Sabina Bandeira Aleixo, Thais Abreu de Almeida, Luiz Henrique de Lima Araújo, Mariana Seibel, Tainá Cabalheiro, Taiane Rebelatto
First-Line Amivantamab-Chemotherapy vs Chemotherapy in NSCLC With EGFR Exon 20 Insertions: Overall Survival From PAPILLON
Chul Kim, Ke-Jing Tang, Byoung Chul Cho, Luis Paz-Ares, Susanna Cheng, Makoto Nishio, Muthukkumaran Thiagarajan, Jonathan W Goldman, Jen-Yu Hung, Josiane Mourão Dias, Sanjay Popat, Joshua K Sabari, Nicolas Girard, Aaron S Mansfield, Keunchil Park, Rachel E Sanborn, Archan Bhattacharya, Praveen Barala, Mohamed Gamil, Shruti Gandhy, Julie Man, Sujay Shah, Caicun Zhou
First-Line Subcutaneous Amivantamab Plus Lazertinib in EGFR-Mutated Advanced NSCLC: Updated Results From the PALOMA-2 Study
First-Line Subcutaneous Amivantamab Plus Lazertinib in EGFR-Mutated Advanced NSCLC: Updated Results From the PALOMA-2 StudyFirst-Line Subcutaneous Amivantamab Plus Lazertinib in EGFR-Mutated Advanced NSCLC: Updated Results From the PALOMA-2 Study
Impact of Common Resistance Mechanisms on Real-World Overall Survival (rwOS) for Patients Receiving Osimertinib
Xiuning Le, Yue Jin, Jin Dai, Levon Demirdjian, Daniel Backenroth, Jiarui Zhang, Joshua C Curtin, Angela Dauti
IPRO-α Response Rate as a Potential Early Endpoint for Overall Survival in MARIPOSA, a Phase 3 Trial in EGFR-Mutated NSCLC
Benjamin Ackerman, Daniel Backenroth, Ariel Bourla, John Xie, Tao Sun, Sujay Shah, Kiran Patel, Brooke Donohue, Angela Dauti, Levon Demirdjian, Omar F. Khan, Natasha B Leighl, Felipe S Torres, Srinivas Raman, Melissa D Curtis, Felix Baldauf-Lenschen, Alison L Mitro, Thomas J Hennessy, Joel Greshock
Overall Survival of 2nd-Line Chemotherapy-Containing Regimens After 1st-Line Osimertinib in EGFR-Mutated Advanced NSCLC
Joshua K. Sabari, Lauren Brown, Pratyusha Vadagam, Yin Wan, Alaina Zaki, Andy L. Johnson
Re-irradiation (ReRT) with NBTXR3 for Inoperable Locoregional Recurrent Non-Small Cell Lung Cancer (NSCLC): A Phase I Trial
Saumil N. Gandhi, Enoch Chang, Aileen B. Chen, Stephen G. Chun, Joe Y. Chang, MD, Steven H. Lin, MD, Matthew S. Ning, MD, David Qian, Julianna K. Bronk, Rahul A. Sheth, Jianjun Zhang, Tina Cascone, Marcelo Vailati Negrao, Anne S. Tsao, George R. Blumenschein, Mehmet Altan, John V. Heymach, James W. Welsh, Zhongxing Liao, Roberto F. Casal
Real-World Characteristics and Treatment Patterns of cEGFRm NSCLC Patients Receiving 2L+ Amivantamab Plus Chemotherapy
Alexander Spira, Ruibin Wang, Cindy Chen, Pratyusha Vadagam, Courtney Morrow, Sanghyuk Seo
Real-World Treatment Patterns and Outcomes After Osimertinib Progression in EGFR-Mutant NSCLC: A Multi-Center Taiwan Study
Shang-Gin Wu, Kai-Cheng Chang, Yi-Chun Chen, Sheau-Pey Wang, Ji-Fan Hsieh, Hsin-Yi Lin, Hui-Yu Chen, Chih-Hsi Kuo, Jin-Yuan Shih
Subcutaneous Amivantamab + Lazertinib With Supportive Care in EGFRm NSCLC: Longer Follow-Up Data From the Pragmatic COPERNICUS Study
Balazs Halmos, Janet Tu, Sarah B. Goldberg, Xiuning Le, Narjust Florez, Wade Iams, Kartik Konduri, Danny Nguyen, Luis Raez, Jonathan Riess, Joshua Sabari, David Bjork, Ticiana Leal, Shiven Patel, Annika Hultén, Yichuan Xia, Paul Cifuentes, Farah Shanoon, Illse Leipoldt, Matthew Gumbleton
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.